Zutectra 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0064 
Minor change in labelling or package leaflet not 
12/02/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0063 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
29/11/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0062 
Minor change in labelling or package leaflet not 
06/11/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0061 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
13/10/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
II/0058 
B.II.d.2.c - Change in test procedure for the finished 
14/04/2023 
n/a 
product - Substantial change to or replacement of a 
biol/immunol/immunochemical test method or a 
method using a biol. reagent or replacement of a 
biol. reference preparation not covered by an 
approved protocol 
IAIN/0059 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
14/03/2023 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0057 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
29/11/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 2/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0056 
B.II.d.2.e - Change in test procedure for the finished 
25/11/2022 
n/a 
product - Update of the test procedure to comply 
with the updated general monograph in the Ph. Eur. 
IB/0055/G 
This was an application for a group of variations. 
31/10/2022 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.b - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
First-time inclusion of a new PMF NOT affecting the 
properties of the FP 
N/0054 
Minor change in labelling or package leaflet not 
29/08/2022 
24/04/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0053 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
17/05/2022 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0052 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/03/2022 
24/04/2023 
SmPC, 
PI has been aligned with the latest QRD template (version 
Veterinary Medicinal Products - Other variation 
Labelling and 
10.2, rev. 1) 
PL 
II/0050 
B.II.e.1.a.3 - Change in immediate packaging of the 
10/02/2022 
n/a 
finished product - Qualitative and quantitative 
Page 3/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
II/0051 
B.II.d.2.c - Change in test procedure for the finished 
13/01/2022 
n/a 
product - Substantial change to or replacement of a 
biol/immunol/immunochemical test method or a 
method using a biol. reagent or replacement of a 
biol. reference preparation not covered by an 
approved protocol 
IAIN/0049 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
10/08/2021 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
202011 
human hepatitis B immunoglobulin 
IAIN/0048 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
17/03/2021 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0046 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
09/07/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 4/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0045 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
13/03/2020 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0044 
B.I.a.2.a - Changes in the manufacturing process of 
10/03/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0043 
B.II.b.2.a - Change to importer, batch release 
07/10/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0041 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
01/08/2019 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0042 
Minor change in labelling or package leaflet not 
31/07/2019 
24/04/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0040/G 
This was an application for a group of variations. 
15/03/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
Page 5/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0039 
Minor change in labelling or package leaflet not 
05/10/2018 
11/04/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0038 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
26/07/2018 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
201711 
human hepatitis B immunoglobulin 
WS/1360 
This was an application for a variation following a 
17/05/2018 
11/04/2019 
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
and PL 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IAIN/0037 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
20/03/2018 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
Page 6/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0034 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
12/10/2017 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IA/0033/G 
This was an application for a group of variations. 
28/07/2017 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
06/07/2017 
n/a 
PRAC Recommendation - maintenance 
201611 
human hepatitis B immunoglobulin 
IAIN/0032 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
10/03/2017 
n/a 
amended PMF in the marketing authorisation dossier 
Page 7/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IAIN/0030 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
03/08/2016 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0029 
Update of the package leaflet with revised contact 
01/08/2016 
11/04/2019 
PL 
details of the local representative for Slovenia. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
07/07/2016 
n/a 
PRAC Recommendation - maintenance 
201511 
human hepatitis B immunoglobulin 
IAIN/0028 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
09/03/2016 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
IB/0026 
B.II.d.2.e - Change in test procedure for the finished 
11/01/2016 
n/a 
product - Update of the test procedure to comply 
with the updated general monograph in the Ph. Eur. 
II/0024 
Extension of Indication to Prevention of hepatitis B 
19/11/2015 
16/12/2015 
SmPC, Annex 
For further information please refer to the published 
virus (HBV) re-infection in HBsAg and HBV-DNA 
II and PL 
Assessment Report: Zutectra H-1089-II-24-AR. 
Page 8/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
negative patients at least one week – instead of the 
approved at least 6 months - after liver 
transplantation for hepatitis B induced liver failure. 
As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 
of the SmPC are updated. The Package Leaflet is 
updated accordingly. In addition, the MAH took the 
opportunity of this procedure to update the Annex II 
in compliance with the QRD template version 9.1. 
An updated RMP version 2 has been agreed. 
The variation leads to amendments to the Summary 
of Product Characteristics, Annex II and Package 
Leaflet and to the Risk Management Plan (RMP). 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IAIN/0025 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
16/10/2015 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
09/07/2015 
n/a 
PRAC Recommendation - maintenance 
201411 
human hepatitis B immunoglobulin 
IAIN/0023 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
13/03/2015 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
Page 9/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
do not affect the properties of the FP 
IB/0021 
B.II.d.2.d - Change in test procedure for the finished 
25/02/2015 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
N/0020 
Minor change in labelling or package leaflet not 
22/01/2015 
16/12/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0019/G 
This was an application for a group of variations. 
12/12/2014 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
R/0015 
Renewal of the marketing authorisation. 
24/07/2014 
16/09/2014 
SmPC, 
Based on the CHMP review of data on quality, safety and 
Labelling and 
efficacy, the CHMP considered by consensus that the risk-
Page 10/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
benefit balance of Zutectra in the prevention of hepatitis B 
virus re-infection in HBV-DNA negative patients ≥ 6 months 
after liver transplantation for hepatitis B induced liver 
failure remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IAIN/0018 
B.II.b.1.a - Replacement or addition of a 
01/09/2014 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
10/07/2014 
n/a 
PRAC Recommendation - maintenance 
201311 
human hepatitis B immunoglobulin 
IAIN/0016 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
05/03/2014 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
PSUSA/1631/
Periodic Safety Update EU Single assessment - 
09/01/2014 
n/a 
PRAC Recommendation - maintenance 
201305 
human hepatitis B immunoglobulin 
IA/0014/G 
This was an application for a group of variations. 
18/12/2013 
06/06/2014 
Annex II 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0011 
Submission of validation data regarding the removal 
24/10/2013 
n/a 
of thrombosis generating agents during the 
Page 11/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing process to comply with the revised 
Eur. Ph. monograph of Human Normal 
Immunoglobulin (0338). 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
N/0012 
Minor change in labelling or package leaflet not 
19/09/2013 
06/06/2014 
PL 
Inclusion of an additional local representative of the MAH 
connected with the SPC (Art. 61.3 Notification) 
for the new Member State, Croatia. 
II/0008 
Update of sections 4.8 and 5.1 of the SmPC and 
27/06/2013 
06/06/2014 
SmPC, Annex 
In study 974, an open, prospective, single-arm clinical 
consequential changes to section 4 of the PIL to 
include the final results from study 974 and study 
978, a PASS, in order to fulfil MEA 002.2.  
Furthermore, the PI is being brought in line with the 
latest QRD template. 
C.I.4 - Variations related to significant modifications 
of the SPC due in particular to new quality, pre-
clinical, clinical or pharmacovigilance data 
II, Labelling 
study investigating the feasibility of home self-
and PL 
administration, efficacy and safety of SC Zutectra in a 
population of stable patients, no re-infection was observed 
and no serious adverse events treatment related were 
reported. 
In study 978, a non-interventional post-authorisation study 
evaluating compliance of patients using SC Zutectra as 
home self-treatment, compliance according to anti-HBs 
serum levels was shown for 93% of patients, no treatment 
failure was observed and no serious adverse events 
treatment related were reported. 
Information regarding the results of these two studies was 
therefore added to the product information. 
II/0009 
Change in the manufacturing process of the active 
30/05/2013 
n/a 
substance. 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological medicinal 
Page 12/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
product and is not related to a protocol 
IAIN/0010 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
26/03/2013 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0007 
Minor change in labelling or package leaflet not 
20/11/2012 
06/06/2014 
PL 
Update of the list of local representatives for Greece, 
connected with the SPC (Art. 61.3 Notification) 
France and Romania. 
IAIN/0006 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
22/06/2012 
n/a 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0005 
Minor change in labelling or package leaflet not 
13/10/2011 
n/a 
PL 
Update of the local representatives contact details for 
connected with the SPC (Art. 61.3 Notification) 
Denmark, France, Island, Norway, Portugal, Finland, 
Sweden and the United Kingdom. 
IA/0004/G 
This was an application for a group of variations. 
12/08/2011 
n/a 
Annex II 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.h - Changes to an existing pharmacovigilance 
Page 13/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IA/0003/G 
This was an application for a group of variations. 
17/12/2010 
n/a 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
B.V.a.1.d - PMF - Inclusion of a new, updated or 
amended PMF in the marketing authorisation dossier 
of a medicinal product. (PMF 2nd step procedure) - 
Inclusion of an updated/amended PMF when changes 
do not affect the properties of the FP 
N/0002 
Minor change in labelling or package leaflet not 
15/12/2010 
n/a 
PL 
Update of the list of the local representatives for Belgium, 
connected with the SPC (Art. 61.3 Notification) 
Spain, Luxembourg, Malta, the Netherlands and Portugal. A 
minor linguistic change was also made in the Italian 
package leaflet. 
IB/0001 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
29/07/2010 
n/a 
SmPC 
life of the finished product - Extension of storage 
period of a biological/immunological medicinal 
product in accordance with an approved stability 
protocol 
Page 14/15 
 
 
 
 
 
 
 
 
 
 
 
 
Page 15/15 
 
 
 
 
 
 
 
